Please assess the completion status of the following clinical trial:

Trial Title: Sequential Treatment of Pediatric MDD to Increase Remission and Prevent Relapse

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Primary diagnosis of nonpsychotic MDD (single or recurrent) for at least 4 weeks before study entry~* In good general medical health~* Normal intelligence~Exclusion Criteria:~* Lifetime history of any psychotic disorder, including psychotic depression~* Lifetime history of bipolar I and II disorders~* Alcohol or substance dependence within the 6 months before study entry~* Anorexia nervosa or bulimia within the 6 months before study entry~* Pregnant or breastfeeding females, or sexually active females not using medically acceptable means of birth control (e.g., IUD, birth control pills, barrier devices)~* Chronic medical illness (medically unstable and requires regular medication that may interfere with treatment interventions)~* Concurrent medication(s) with psychotropic effects (e.g., anticonvulsants, steroids, etc.) other than stable ADHD medication~* First degree relatives with bipolar I disorder~* Severe suicidal ideation or previous history of serious suicide attempt within this episode~* Prior failure to respond to an adequate treatment with fluoxetine (defined as at least 40 mg/day for 4 weeks)~* Non-English speaking

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Continued medication alone (Type: ACTIVE_COMPARATOR): Participants will receive antidepressant treatment with fluoxetine for 30 weeks
- Continued medication plus CBT (Type: EXPERIMENTAL): Participants will receive antidepressant treatment with fluoxetine for 30 weeks plus relapse prevention cognitive behavioral therapy for the last 24 weeks of treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).